Newsbenzinga
Vaxcyte Stock Hits New 52-Week High - Here’s Why
· Published
Article summary
Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.
An excerpt from the original article.
Comments —
Loading comments…